Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
1999-08-25
2003-04-08
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
C530S300000, C530S387100, C530S387300
Reexamination Certificate
active
06545124
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to covalently linked polypeptide cell modulators, each of which acts through a different and specific cell receptor to initiate complementary biological activities. Polypeptide cell modulators include lymphokines, monokines, interferons, polypeptide hormones or cytotoxins as well as modifications and active segments of such peptides. Also described are DNA sequences, plasmids and hosts capable of expressing the linked polypeptide cell modulators.
2. Description of Prior Art
One class of polypeptide cell modulators can be defined whose members exert an antiproliferative effect almost specifically on tumour cells and possess immunomodulatory activity, but lack antiviral activity. Among the members of this class are human lymphotoxin and tumour necrosis factor (Gray, P. W. et al. Nature 312, 721, 1984; Pennica D. et al. Nature 312, 724, 1984).
Human lymphotoxin (hLT) is a cytotoxin induced in lymphocytes by a specific antigen or by bacteria or parasites and has a cytotoxic or cytostatic action on a variety of tumour cells in vivo or in vitro. hLT has been implicated to play a role in cell-mediated immunity and its potent anti-tumour effect suggests it may be of value therapeutically (Ruddle, N. H. et al. Lymphokine Res. 2, 23, 1983).
Another class of lymphokine can be defined whose members induce an antiviral state in responsive cells, and also have antiproliferative and immunomodulating activity. Among the members of this class are leukocyte interferon (IFN-alpha), fibroblast interferon (IFN-beta) and immune interferon (IFN-gamma).
It has been reported that mixtures of type I interferons (IFN-beta or IFN-alpha) and type II interferons (IFN-gamma) are highly synergistic in exerting an antiviral or antiproliferative effect. (Fleishmann, W. R. et al. Infect. Immun. 26, 248, 1979; Czarniecki, C. W. et al. J. Virol. 49, 490, 1984).
In mixtures, much lower concentrations of type I and type II interferons can achieve a particular level of response. Several authors have also described IFN-gamma/hLT and IFN-alpha/hLT synergy or related synergies (Lee, S. H. et al. J. Immunol. 133, 1083, 1984; Stone-wolff, D. S. et al. J. Exp. Med. 159, 828, 1984; Williams, T. W. Lymphokine Res. 3, 113, 1984), European Patent Application (EPO 107 498), (EPO 128009).
However, in these instances, there was no disclosure of covalent linkage of the two classes of molecules that were synergistic.
Additional patent publications have described the primary amino acid sequences of human IFN-gamma (GB 2 107 718 A), the IFN-gamma (IFN X918) described herein (PCT 83/04053), IFN-alphas (U.S. Pat. No. 4,414,150- Aug. 11, 1983) and IFN-beta (e.g. GB 0689 70B; GB 2098996A). A modified IFN-beta (IFN X430) described herein is identical to human fibroblast IFN-beta except that amino acids 36 to 48 inclusive are replaced with amino acids 34 to 46 inclusive from human IFN-alpha 1 (European Patent Application 85105914.7 and (Taniguchi, T. at al. Nature 285, 547, 1980).
BRIEF DESCRIPTION OF THE INVENTION
This invention encompasses mixed function proteins formed from covalently linked polypeptide cell modulators, each of which acts through a different and specific cell receptor to initiate complementary biological activities. Novel compounds of this invention are represented by the formula
R
1
—L—R
2
where R
1
is a polypeptide cell modulator with one activity, R
2
is a polypeptide cell modulator with a different but complementary activity. By complementary activity is meant activity which enhances or changes the response to another cell modulator. The polypeptide cell modulators are either directly bonded to one another or are each bound to a polypeptide linker segment. Thus L represents a chemical bond or a polypeptide linker segment to which both R
1
and R
2
are bound, most commonly L is a linear peptide to which R
1
and R
2
are bound by amide bonds linking the carboxy terminus of R
1
to the amino terminus of L and the carboxy terminus of L to the amino terminus of R
2
. The linking group is generally a polypeptide of between 1 and 500 amino acids in length.
The term polypeptide cell modulator encompasses a large variety of peptides which elicit a biological response by binding to a specific binding site on a cell. It is known that mixtures of polypeptide cell modulators such as beta and gamma interferon exhibit a synergistic effect. In this invention the polypeptide cell modulators are bound together to produce the same synergistic effect as a mixture of the polypeptide cell modulators or a further enhanced effect or a different effect with the advantage of a single dosage form.
Compounds of this invention are preferably made by genetic engineering techniques. Thus genetic material (DNA) coding for one polypeptide cell regulator, peptide linker segment and the other polypeptide cell regulator is inserted into a suitable vector which is used to transform bacteria, yeast or mammalian cells. The transformed organism is grown and the protein isolated by standard techniques. The resulting product is therefore a new protein which has two complementary cell regulatory regions joined by a peptide linker segment as shown in the formula R
1
—L—R
2
, wherein R
1
and R
2
represent polypeptide cell regulator regions and L represents the peptide linker segment.
REFERENCES:
patent: 4468382 (1984-08-01), Bacha et al.
patent: 4691009 (1987-09-01), Palmer et al.
patent: 4734491 (1988-03-01), Caruthers
patent: RE32637 (1988-04-01), Ishida
patent: 4758428 (1988-07-01), Mark et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4921699 (1990-05-01), DeChiara et al.
patent: 5292668 (1994-03-01), Paulus
patent: 0 141 484 (1985-05-01), None
patent: 0 158 198 (1985-10-01), None
patent: 0 237 019 (1987-09-01), None
patent: 83/02461 (1983-07-01), None
patent: 85/02198 (1985-05-01), None
Yamawaki-Kataoka at el. Nature 283:786-789 1980.*
Ngo et al. in “The Protein Folding Problem and Tertiary Structure Prediction” K. Merz, Jr and S. Le Grand, ed; Birkhauser Boston 1994; see pp. 14-491-495.*
Ito et al. Biochem. 1985; 24:6467-6474.*
Oi et al. Nature Jan. 1984; 307:136-140.*
Wolfenstein-Todel et al. Biochem. 1972;11(21):3971-5.*
Takayasu et al. Biochem. Biophys. Res. Com. 1982;105(3):1066-71.*
Adlersberg et al. Proc. Natl. Acad. Sci. USA 1975;73(2):723-727.*
de Preval et al. Nature 1970;228:930-932.*
Hiramatsu et al. Recombinant Plasmid Containing Human Urokinase etc., Chem. Abstract; pp. 159 1987, Abstract #106:62196j.
Shepard et al. “A Single Amino Acid Change in IFN-BETA1 etc.” Nature vol. 294 pp. 563-565 1981.
Rudinger, “Characteristics of the Amino Acids as etc.” in Peptide Hormones ed J.A. Pargone, University Park Press 1976, pp. 1-7.
Bell Leslie David
McCullagh Keith Graham
Porter Alan George
Bauer S. Christopher
Gambel Phillip
Pharmacia Corporation
Roark Jessica H.
LandOfFree
Peptide linkers for covalent linking polypeptide cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide linkers for covalent linking polypeptide cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide linkers for covalent linking polypeptide cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3082826